Biotech Support Group reports on the simplicity and efficiency of their hemoglobin depletion technology

Biotech Support Group reports on a recent research article describing the describing the simplicity and efficiency of their hemoglobin depletion technology for improving the signal from an exosome assay obtained from hemolyzed mouse sera.

The study considers that therapeutic strategies targeting cancer-derived extracellular vesicles (EVs) hold great promise because of the possibility they reposition microenvironments to accommodate metastasis. The researchers report on a novel strategy of therapeutic antibody treatment to target cancer-derived EVs and inhibit the metastasis of breast cancer in a mouse model.

The article states “Hemoglobin was accumulated with HemogloBind beads (Biotech support group, Monmouth Junction NJ, USA) followed by 0.22 μm filtration. Then, the EVs in the sera were concentrated by ultracentrifugation”. The authors conclude that therapeutic antibody administration effectively suppresses EV-triggered metastasis and that the elimination of cancer-exosome derived EVs could be a novel strategy for therapy.

“I am very pleased that this article demonstrates the importance of removing hemoglobin from hemolyzed mouse sera, and that Hemoglobind treatment significantly improved the signals of the exosome assay. The study demonstrates the importance of exosomes in cancer pathogenesis and suggests an exciting new therapeutic strategy” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

Reference:
Nishida-Aoki, N., Tominaga, N., Takeshita, F., Sonoda, H., Yoshioka, Y., & Ochiya, T. (2017). Disruption of circulating Extracellular Vesicles as a novel therapeutic strategy against cancer Metastasis. Molecular Therapy, 25(1), 181–191. doi:10.1016/j.ymthe.2016.10.009

Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.